ENZ - Enzo Biochem, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
New York,
United States
Type: Equity
ENZ price evolution
ENZ
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 1 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.16 | $60.24 | ||
| Short term investments | ||||
| Net receivables | $3.99 | $3.94 | $5.12 | $4.18 |
| Inventory | $6.83 | $7.32 | $7.8 | $7.59 |
| Total current assets | $70.03 | $75.74 | $80.92 | $88.01 |
| Long term investments | ||||
| Property, plant & equipment | $15.2 | $15.6 | $16.02 | $16.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.73 | $18.16 | ||
| Total investments | ||||
| Total assets | $85.76 | $93.47 | $99.08 | $106.31 |
| Current liabilities | ||||
| Accounts payable | $1.38 | $1.52 | $1.32 | $1.96 |
| Deferred revenue | ||||
| Short long term debt | $4.48 | $4.09 | ||
| Total current liabilities | $24.79 | $21.66 | $25.28 | $28.84 |
| Long term debt | $0.19 | $0.18 | $0.23 | $0.22 |
| Total noncurrent liabilities | $2.77 | $3.02 | ||
| Total debt | $7.26 | $7.11 | ||
| Total liabilities | $29.65 | $24.44 | $28.3 | $32.03 |
| Shareholders' equity | ||||
| Retained earnings | -$294.43 | -$281.05 | -$278.03 | -$274.97 |
| Other shareholder equity | $1.89 | $2.5 | $2.05 | $2.75 |
| Total shareholder equity | $69.03 | $70.78 | ||
| (in millions $) | 31 Aug 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.37 | $21.6 | $13.52 | |
| Short term investments | $29.98 | |||
| Net receivables | $3.99 | $4.81 | $11.52 | $10.2 |
| Inventory | $6.83 | $7.94 | $15.41 | $12.65 |
| Total current assets | $70.03 | $98.46 | $54.35 | $70.58 |
| Long term investments | ||||
| Property, plant & equipment | $15.2 | $16.71 | $32.43 | $33.6 |
| Goodwill & intangible assets | $7.45 | $7.7 | ||
| Total noncurrent assets | $23.42 | $41.5 | $43.11 | |
| Total investments | $29.98 | |||
| Total assets | $85.76 | $121.88 | $95.86 | $113.69 |
| Current liabilities | ||||
| Accounts payable | $1.38 | $3.58 | $8.51 | $8.12 |
| Deferred revenue | ||||
| Short long term debt | $3.49 | $3.74 | $3.65 | |
| Total current liabilities | $24.79 | $39.99 | $24.55 | $26.08 |
| Long term debt | $0.19 | $3.43 | $16.84 | $19.03 |
| Total noncurrent liabilities | $3.43 | $16.84 | $19.03 | |
| Total debt | $6.92 | $20.59 | $22.68 | |
| Total liabilities | $29.65 | $43.42 | $41.4 | $45.1 |
| Shareholders' equity | ||||
| Retained earnings | -$294.43 | -$268.35 | -$288.64 | -$270.38 |
| Other shareholder equity | $1.89 | $1.88 | $3.15 | $1.35 |
| Total shareholder equity | $78.46 | $54.46 | $68.59 | |
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 1 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.53 | $8.02 | $8.55 | $7.81 |
| Cost of revenue | ||||
| Gross Profit | $3.22 | $3.73 | $4.22 | $3.46 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.78 | $5.08 | $5.65 | $7.86 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.4 | $0.2 | $1.59 | -$0.03 |
| Net income | ||||
| Net income | -$13.38 | -$3.02 | -$3.06 | -$6.62 |
| Income (for common shares) | ||||
| (in millions $) | 31 Aug 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $31.91 | $31.06 | $107.07 | $117.73 |
| Cost of revenue | $19.5 | $65.1 | $64.15 | |
| Gross Profit | $14.63 | $11.57 | $41.97 | $53.58 |
| Operating activities | ||||
| Research & development | $3.9 | $3.77 | $3.25 | |
| Selling, general & administrative | $32.4 | $53.71 | $49.63 | |
| Total operating expenses | $24.36 | $36.3 | $56.97 | $52.88 |
| Operating income | -$24.74 | -$15.01 | $0.69 | |
| Income from continuing operations | ||||
| EBIT | $21.41 | -$18.42 | $7.87 | |
| Income tax expense | ||||
| Interest expense | $3.15 | $1.12 | -$0.16 | -$0.01 |
| Net income | ||||
| Net income | -$26.08 | $20.29 | -$18.26 | $7.88 |
| Income (for common shares) | $20.29 | -$18.26 | $7.88 | |
| (in millions $) | 31 Aug 2024 | 30 May 2024 | 2 Mar 2024 | 1 Dec 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.55 | -$0.42 | -$0.28 | -$0.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$4.19 | -$0.58 | -$0.54 | -$0.52 |
| Effect of exchange rate | -$0.01 | -$0.04 | -$0 | -$0.02 |
| Change in cash and equivalents | -$31 | -$26.22 | -$23.13 | -$14.17 |
| (in millions $) | 31 Aug 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $20.29 | -$18.26 | $7.88 | |
| Operating activities | ||||
| Depreciation | $2.68 | $2.83 | $2.65 | |
| Business acquisitions & disposals | $101.74 | |||
| Stock-based compensation | $3.15 | $2.34 | $1.64 | |
| Total cash flows from operations | -$36.98 | -$16.59 | $0.39 | |
| Investing activities | ||||
| Capital expenditures | -$2.76 | -$3.47 | -$4.44 | |
| Investments | $28.7 | -$30.06 | ||
| Total cash flows from investing | -$0.55 | $98.98 | $25.22 | -$34.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.4 | $0.03 | $0.1 | |
| Net borrowings | -$1.52 | -$0.27 | -$0.34 | |
| Total cash flows from financing | -$4.19 | -$1.13 | -$0.24 | -$0.24 |
| Effect of exchange rate | -$0.01 | -$0.11 | -$0.06 | $0.01 |
| Change in cash and equivalents | -$31 | $60.77 | $8.33 | -$34.34 |
News
Fundamentals
| Market cap | $50.68M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 52.24M |
| Revenue | $31.91M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$26.08M |
| Revenue Q/Q | -75.77% |
| Revenue Y/Y | -60.04% |
| P/E ratio | -1.94 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.59 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.50 |
|---|---|
| ROA | -27.12% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.82 |
| Quick ratio | 2.55 |